摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4R)-2-[(2S)-2-(3,4-dichlorophenyl)pent-4-en-1-yl]-4-methyl-1-oxo-1,3,4,6-tetrahydro-2H-naphtho[1,2-f][1,4]oxazocine-7-carbonitrile | 367261-19-6

中文名称
——
中文别名
——
英文名称
(4R)-2-[(2S)-2-(3,4-dichlorophenyl)pent-4-en-1-yl]-4-methyl-1-oxo-1,3,4,6-tetrahydro-2H-naphtho[1,2-f][1,4]oxazocine-7-carbonitrile
英文别名
——
(4R)-2-[(2S)-2-(3,4-dichlorophenyl)pent-4-en-1-yl]-4-methyl-1-oxo-1,3,4,6-tetrahydro-2H-naphtho[1,2-f][1,4]oxazocine-7-carbonitrile化学式
CAS
367261-19-6
化学式
C27H24Cl2N2O2
mdl
——
分子量
479.406
InChiKey
LAAWWKOTDOMHEN-YLJYHZDGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.74
  • 重原子数:
    33.0
  • 可旋转键数:
    5.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    53.33
  • 氢给体数:
    0.0
  • 氢受体数:
    3.0

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (4R)-2-[(2S)-2-(3,4-dichlorophenyl)pent-4-en-1-yl]-4-methyl-1-oxo-1,3,4,6-tetrahydro-2H-naphtho[1,2-f][1,4]oxazocine-7-carbonitrile臭氧二甲基硫 作用下, 以 甲醇二氯甲烷 为溶剂, 以47%的产率得到(R)-11-[(S)-2-(3,4-Dichloro-phenyl)-4-oxo-butyl]-9-methyl-12-oxo-9,10,11,12-tetrahydro-7H-8-oxa-11-aza-cycloocta[a]naphthalene-6-carbonitrile
    参考文献:
    名称:
    Naphtho[2,1-b][1,5] and [1,2-f][1,4]oxazocines as selective NK1 antagonists
    摘要:
    Previously we reported on the synthesis and properties of a series of highly potent piperidinyl 2-subsituted-3-cyano-1-naphthamide NK1 antagonists that includes 3 and 4. Here we report our efforts to alleviate a troublesome atropisomeric property of those derivatives by introduction of a tethering bridge that, in addition, could be used to lock the resulting cyclic derivatives in a purported NK1 pharmacophore conformation. Using 3 as a starting point, the naphtho[2, 1-b][1,5]oxazocine, 17, was found to contain the optimal ring tether size (8) for retaining NK1 activity, was more NK1 versus NK2 selective, and reduced the number of atropisomers from four to two. Cyclic derivatives 29 and 32, which exist as essentially single atropisomers in the purported pharmacophore conformation. were prepared in the closely related naphtho[1,2-f][1,4]oxazocine series as part of an effort to use mono methyl substitution of the tethering bridge as a conformation stabilizing factor. Both 29 and 32 were found to be less active as NK1 antogonists than the non-methylated parent 28 possibly due to methyl group destabilization of receptor interaction. We discuss the above findings in the context of a previously proposed NK1 pharmacophore model and present a further refinement of that model. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2004.03.015
  • 作为产物:
    参考文献:
    名称:
    Naphtho[2,1-b][1,5] and [1,2-f][1,4]oxazocines as selective NK1 antagonists
    摘要:
    Previously we reported on the synthesis and properties of a series of highly potent piperidinyl 2-subsituted-3-cyano-1-naphthamide NK1 antagonists that includes 3 and 4. Here we report our efforts to alleviate a troublesome atropisomeric property of those derivatives by introduction of a tethering bridge that, in addition, could be used to lock the resulting cyclic derivatives in a purported NK1 pharmacophore conformation. Using 3 as a starting point, the naphtho[2, 1-b][1,5]oxazocine, 17, was found to contain the optimal ring tether size (8) for retaining NK1 activity, was more NK1 versus NK2 selective, and reduced the number of atropisomers from four to two. Cyclic derivatives 29 and 32, which exist as essentially single atropisomers in the purported pharmacophore conformation. were prepared in the closely related naphtho[1,2-f][1,4]oxazocine series as part of an effort to use mono methyl substitution of the tethering bridge as a conformation stabilizing factor. Both 29 and 32 were found to be less active as NK1 antogonists than the non-methylated parent 28 possibly due to methyl group destabilization of receptor interaction. We discuss the above findings in the context of a previously proposed NK1 pharmacophore model and present a further refinement of that model. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2004.03.015
点击查看最新优质反应信息

同类化合物

黄药子素C 黄独素A 香紫苏内酯 降龙涎香醚 阿霉素(α-β混合物) 银线草内酯醇 辛辣木素 载脂蛋白-土霉素 萘并[2,3-c]呋喃-3(1H)-酮 萘并[2,3-c]呋喃-1,3-二酮,5,8-二甲基-(9CI) 萘并[2,3-c]呋喃-1(3H)-酮,4-(3-呋喃基)-7-羟基- 萘并[2,3-b]呋喃-4,9-二酮,2,3-二氢-2-甲基-2-苯基- 萘并[2,1-b]呋喃-2-甲酰肼 萘并[2,1-b]呋喃-2(1H)-酮 萘并[2,1-b]呋喃-1-乙酸 萘并[1,2-b]呋喃-2-醇,2,3,3a,4,5,5a,6,7,9a,9b-十氢-3,5a,9-三甲基- 萘并[1,2-b]呋喃-2(3H)-酮,3a,4,5,9b-四氢-8-羟基-3,9-二甲基-,(3R,3aR,9bS)-rel- 萘并(2,3-b)呋喃-4,9-二酮 萘[2,1-b]呋喃-2-羧酸乙酯 萘[2,1-B]苯并呋喃-10-基硼酸 荧蒽-2,3-二甲酸酐 苯并[g][1]苯并呋喃-8,9-二酮 苯并[g][1]苯并呋喃-3-酮 苯并[g][1]苯并呋喃-2-甲醛 苯并[g][1]苯并呋喃 苯并[f][1]苯并呋喃-3-酮 苯并[e][1]苯并呋喃-8-醇 苯并[e][1]苯并呋喃-1-酮 苯并[e][1]苯并呋喃 苯并[b]萘并[2,3-d]呋喃 苯并[b]萘并[2,1-d]呋喃 苯并[b]萘并[1,2-d]呋喃 苯并[B]萘并[2,3-D]呋喃-2-羟基硼酸 苯基利福平 苯基(6,7,8,9-四氢萘并[2,1-b]呋喃-2-基)甲醇 苊并[5,4-b]呋喃-4,5-二酮,7,8-二氢-3,6-二羟基-1,7,7,8-四甲基-,(8S)- 维生素K1相关化合物 红葱酚 盐(1:2)苯磺酸,2,2'-(1,2-乙烯二基)二[5-[[4,6-二(2-萘氧基)-2-嘧啶基]氨基]-,钠 白术内酯 I 珀勒内B 珀勒内A 沃拉帕沙杂质 沃拉帕沙 沃拉帕沙 沃拉帕沙 己二酸,聚合2,2-二(羟甲基)-1,3-丙二醇,1,3-异苯并呋喃二酮和2,2-氧代二乙醇,2-丙烯酸酯 岩大戟内酯B 岩大戟内酯A 密叶辛木素